Precision therapeutics for major unmet medical needs
About Us
Changing the way we treat disease
We have a decade of data informing our strategy including patient responder analyses, rigorous dose modeling and flawless clinical execution. As a result, our therapeutic candidates have maximum potential for patient impact. Find out more about the SPRING trial for P. gingivalis positive Alzheimer's disease.
News & Events
Lighthouse Pharmaceuticals to Present Phase 2 SPRING Trial of LHP588, a Next-Generation Gingipain Inhibitor for the Treatment of P. gingivalis-Positive Alzheimer’s Disease, at CTAD 2025
Lighthouse Pharmaceuticals Relocates Headquarters to the Buck Institute for Research on Aging
Phibro Animal Health Corporation Announces Licensing Agreement with Lighthouse Pharmaceuticals, Inc. for Innovative Periodontal Health Asset for Dogs
Lighthouse Pharmaceuticals Receives $49.2 Million Grant from NIA to Advance Phase 2 Study of LHP588 for P. gingivalis-Positive Alzheimer’s Disease
Groundbreaking Clinical Trial to Enroll 300 Patients in Double-Blind, Placebo-Controlled Study of Lysine-Gingipain Inhibitor
Lighthouse Pharmaceuticals Initiates Phase 2 SPRING Trial of LHP588 in P. gingivalis-Positive Alzheimer’s Disease
48-Week Study to Evaluate the Safety and Efficacy of Oral LHP588 Dosed Once Daily
